Prot #6R88-COV-2040: An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients with COVID-19

Project: Research project

Project Details

StatusActive
Effective start/end date3/17/203/20/23

Funding

  • Regeneron Pharmaceuticals, Inc. (Prot #6R88-COV-2040)